General
Preferred name
NEVIRAPINE
Synonyms
LAMIVUDINE ()
NSC 641530 ()
NVP ()
BI-RG 587 ()
Nevirapine (Viramune) ()
Viramune ()
Nevirapine (NSC 641530) ()
NSC 641530,NVP ()
BIRG-0587 ()
Viramune Xr ()
BIRG 0587 ()
NSC-641530 ()
Nevirapine anhydrous ()
Nevirapine teva ()
Nevirapine, anhydrous ()
Nevirapinum anhydrous ()
Nevirapine-d4 ()
P&D ID
PD000851
CAS
129618-40-2
1051418-95-1
Tags
natural product
drug
available
Approved by
EMA
FDA
First approval
1996
Drug Status
approved
Drug indication
Human immunodeficiency virus infection
Antiviral
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) class antiretriviral drug. (GtoPdb)
Cell lines
7
Organisms
4
Compound Sets
27
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
JUMP-Target 1 Compound Set
Ki Database
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
External IDs
50
Properties
(calculated by RDKit )
Molecular Weight
266.12
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
1
Ring Count
4
Aromatic Ring Count
2
cLogP
2.65
TPSA
58.12
Fraction CSP3
0.27
Chiral centers
0.0
Largest ring
7.0
QED
0.86
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Pathway
Microbiology&virology
Proteases/Proteasome
Anti-infection
Target
HIV-1 reverse transcriptase
CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP3A4, CYP3A5
NNRT inhibitor
CYP2A6
HIV
Parasite
Reverse Transcriptase
Indication
human immunodeficiency virus (HIV-1)
MOA
non-nucleoside reverse transcriptase inhibitor
Therapeutic Class
Anti-HIV Agents
Source data